Methoxyamine hydrochloride is a Small Molecule owned by TRACON Pharmaceuticals, and is involved in 8 clinical trials, of which 4 were completed, 3 are ongoing, and 1 is planned.
TRC102 (methoxyamine hydrochloride) acts by covalently binding to apurinic/apyrimidinic (AP) DNA damage sites and inhibits base excision repair (BER), which results in an increase in DNA strand breaks and apoptosis. It blocks the ability of a cell to repair DNA damage and kill the cancer cells.
The revenue for Methoxyamine hydrochloride is expected to reach a total of $384m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Methoxyamine hydrochloride NPV Report.
Methoxyamine hydrochloride Overview
TRC-102 (methoxyamine hydrochloride) is under development for the treatment of advanced or metastatic solid tumors, lung cancer, glioblastoma multiforme (GBM), lymphoma, ovarian cancer, colorectal cancer, mesothelioma. It is administered through oral and intravenous route. It is an inhibitor of base-excision repair intended to reverse resistance to alkylator and antimetabolite chemotherapy. It was under development for the treatment of relapsed or refractory hematologic malignancies, multiple myeloma,chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia, Hodgkin Lymphoma, diffuse large B-Cell lymphoma, nodal T-Cell Lymphomas, mantle cell lymphoma, anaplastic large cell lymphoma and follicular lymphoma
TRACON Pharmaceuticals Overview
TRACON Pharmaceuticals (TRACON) is a biopharmaceutical company. It develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its lead product TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC102 is a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. In addition, it also offers products for the treatment of fibrosis, prostate cancer, and hematologic malignancies such as myeloma. The company works in collaboration with universities and medical institutions. TRACON is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$28.4 million in FY2021, compared to an operating loss of US$16.2 million in FY2020. The net loss of the company was US$28.7 million in FY2021, compared to a net loss of US$16.8 million in FY2020.
Quick View – Methoxyamine hydrochloride
|Highest Development Stage|